Pharsight

Jesduvroq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11643397 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(4 years from now)

US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(3 years from now)

US11649217 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(13 years from now)

Jesduvroq is owned by Glaxosmithkline.

Jesduvroq contains Daprodustat.

Jesduvroq has a total of 6 drug patents out of which 0 drug patents have expired.

Jesduvroq was authorised for market use on 01 February, 2023.

Jesduvroq is available in tablet;oral dosage forms.

Jesduvroq can be used as a method of treating anemia, treatment of anemia due to chronic kidney disease.

Drug patent challenges can be filed against Jesduvroq from 01 February, 2027.

The generics of Jesduvroq are possible to be released after 13 March, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 01, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date:

01 February, 2027

Market Authorisation Date:

01 February, 2023

Treatment:

Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage:

TABLET;ORAL

More Information on Dosage

JESDUVROQ family patents

Family Patents